Association of natural killer cells in allografts with transplant outcomes in patients receiving G-CSF-mobilized PBSC grafts and G-CSF-primed BM grafts from HLA-haploidentical donors

Bone Marrow Transplantation

Volumn 44, Issue 11, 2009, Pages 721-728

  Zhao, X Y ^a   Chang, Y J ^a   Xu, L P ^a   Liu, D H ^a   Liu, K Y ^a   Huang, X J ^a  

^a PEKING UNIVERSITY   (China)

Author keywords

CD56bright NK cells; GVHD; Haploidentical; HLA mismatched; HSCT

Indexed keywords

BUSULFAN; CD56 ANTIGEN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTARABINE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; SEMUSTINE; THYMOCYTE ANTIBODY;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; BONE MARROW; CANCER SURVIVAL; CHRONIC GRAFT VERSUS HOST DISEASE; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; DONOR; FEMALE; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HLA MATCHING; HUMAN; IMMUNOPHENOTYPING; INCIDENCE; MALE; MYELODYSPLASTIC SYNDROME; NATURAL KILLER CELL; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; STEM CELL MOBILIZATION;

ADULT; ANTIGENS, CD56; BONE MARROW CELLS; DISEASE-FREE SURVIVAL; FEMALE; GRAFT VS HOST DISEASE; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY TESTING; HLA ANTIGENS; HUMANS; KILLER CELLS, NATURAL; MALE; TISSUE DONORS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 75049083645     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2009.73     Document Type: Article

References (37)

1. Ruggeri L, Capanni M, Urbani E, Perruccio K, Shlomchik WD, Tosti A et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002; 295: 2097-2100.
2. Aversa F. Haploidentical haematopoietic stem cell transplantation for acute leukaemia in adults: experience in Europe and the United States. Bone Marrow Transplant 2008; 41: 473-481.
3. Koh LP, Rizzieri DA, Chao NJ. Allogeneic hematopoietic stem cell transplant using mismatched/haploidentical donors. Biol Blood Marrow Transplant 2007; 13: 1249-1267.
4. Liu DH, Huang XJ, Liu KY, Xu LP, Chen H, Han W et al. Haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for treatment of hematological malignancies in children. Biol Blood Marrow Transplant 2008; 14: 469-477.
5. Huang XJ, Liu DH, Liu KY, Xu LP, Chen H, Han W et al. Haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion for the treatment of hematological malignancies. Bone Marrow Transplant 2006; 38: 291-297.
6. Lu DP, Dong L, Wu T, Huang XJ, Zhang MJ, Han W et al. Conditioning including antithymocyte globulin followed by unmanipulated HLA-mismatched/ haploidentical blood and marrow transplantation can achieve comparable outcomes with HLA-identical sibling transplantation. Blood 2006; 107: 3065-3073.
7. Cooper MA, Fehniger TA, Caligiuri MA. The biology of human natural killer-cell subsets. Trends Immunol 2001; 22: 633-640.
8. Farag SS, Fehniger TA, Ruggeri L, Velardi A, Caligiuri MA. Natural killer cell receptors: new biology and insights into the graft-versus-leukemia effect. Blood 2002; 100: 1935-1947.
9. Chang YJ, Zhao XY, Huang XJ. Effects of the NK cell recovery on outcomes of unmanipulated haploidentical blood and marrow transplantation for patients with hematologic malignancies. Biol Blood Marrow Transplant 2008; 14: 323-334.
10. Pascal V, Brunet C, Pradel V, Thirion X, Andre P, Faucher C et al. Analysis of donor NK and T cells infused in patients undergoing MHC-matched allogeneic hematopoietic transplantation. Leukemia 2002; 16: 2259-2266.
11. Ruggeri L, Mancusi A, Burchielli E, Capanni M, Carotti A, Aloisi T et al. NK cell alloreactivity and allogeneic hematopoietic stem cell transplantation. Blood Cells Mol Dis 2008; 40: 84-90.
12. Ruggeri L, Mancusi A, Capanni M, Urbani E, Carotti A, Aloisi T et al. Donor natural killer cell allorecognition of missing self in haploidentical hematopoietic transplantation for acute myeloid leukemia: challenging its predictive value. Blood 2007; 110: 433-440.
13. Yamasaki S, Henzan H, Ohno Y, Yamanaka T, Iino T, Itou Y et al. Influence of transplanted dose of CD56+ cells on development of graft-versus-host disease in patients receiving G-CSF-mobilized peripheral blood progenitor cells from HLA-identical sibling donors. Bone Marrow Transplant 2003; 32: 505-510.
14. Kim DH, Sohn SK, Lee NY, Baek JH, Kim JG, Won DI et al. Transplantation with higher dose of natural killer cells associated with better outcomes in terms of non-relapse mortality and infectious events after allogeneic peripheral blood stem cell transplantation from HLA-matched sibling donors. Eur J Haematol 2005; 75: 299-308.
15. Huang XJ, Zhao XY, Liu DH, Liu KY, Xu LP. Deleterious effects of KIR ligand incompatibility on clinical outcomes in haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion. Leukemia 2007; 21: 848-851.
16. Zhao XY, Huang XJ, Liu KY, Xu LP, Liu DH. Prognosis after unmanipulated HLA-haploidentical blood and marrow transplantation is correlated to the numbers of KIR ligands in recipients. Eur J Haematol 2007; 78: 338-346.
17. Zhao XY, Huang XJ, Liu KY, Xu LP, Liu DH. Reconstitution of natural killer cell receptor repertoires after unmanipulated HLA-mismatched/ haploidentical blood and marrow transplantation: analyses of CD94:NKG2A and killer immunoglobulin-like receptor expression and their associations with clinical outcome. Biol Blood Marrow Transplant 2007; 13: 734-744.
18. Larghero J, Rocha V, Porcher R, Filion A, Ternaux B, Lacassagne MN et al. Association of bone marrow natural killer cell dose with neutrophil recovery and chronic graftversus-host disease after HLA identical sibling bone marrow transplants. Br J Haematol 2007; 138: 101-109.
19. Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 1974; 18: 295-304.
20. Caligiuri MA, Zmuidzinas A, Manley TJ, Levine H, Smith KA, Ritz J. Functional consequences of interleukin 2 receptor expression on resting human lymphocytes. Identification of a novel natural killer cell subset with high affinity receptors. J Exp Med 1990; 171: 1509-1526.
21. Ruggeri L, Capanni M, Casucci M, Volpi I, Tosti A, Perruccio K et al. Role of natural killer cell alloreactivity in HLAmismatched hematopoietic stem cell transplantation. Blood 1999; 94: 333-339.
22. Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: New representations of old estimators. Stat Med 1999; 18: 695-706.
23. Diez-Campelo M, Perez-Simon JA, Ocio EM, Castilla C, Gonzalez-Porras JR, Sanchez-Guijo FM et al. CD34 + cell dose and outcome of patients undergoing reduced-intensityconditioning allogeneic peripheral blood stem cell transplantation. Leuk Lymphoma 2005; 46: 177-183.
24. Gorin NC, Labopin M, Rocha V, Arcese W, Beksac M, Gluckman E et al. Marrow versus peripheral blood for geno-identical allogeneic stem cell transplantation in acute myelocytic leukemia: influence of dose and stem cell source shows better outcome with rich marrow. Blood 2003; 102: 3043-3051.
25. Mohty M, Blaise D, Faucher C, Bardou VJ, Gastaut JA, Viens P et al. Impact of plasmacytoid dendritic cells on outcome after reduced-intensity conditioning allogeneic stem cell transplantation. Leukemia 2005; 19: 1-6. (Pubitemid 40090067)
26. Nakamura R, Auayporn N, Smith DD, Palmer J, Sun JY, Schriber J et al. Impact of graft cell dose on transplant outcomes following unrelated donor allogeneic peripheral blood stem cell transplantation: higher CD34+ cell doses are associated with decreased relapse rates. Biol Blood Marrow Transplant 2008; 14: 449-457.
27. Perez-Simon JA, Diez-Campelo M, Martino R, Sureda A, Caballero D, Canizo C et al. Impact of CD34+ cell dose on the outcome of patients undergoing reduced-intensity-conditioning allogeneic peripheral blood stem cell transplantation. Blood 2003; 102: 1108-1113.
28. Shaw BE, Russell NH, Devereux S, Das-Gupta E, Mackinnon S, Madrigal JA et al. The impact of donor factors on primary non-engraftment in recipients of reduced intensity conditioned transplants from unrelated donors. Haematologica 2005; 90: 1562-1569.
29. Storek J. Immunological reconstitution after hematopoietic cell transplantation-its relation to the contents of the graft. Expert Opin Biol Ther 2008; 8: 583-597.
30. Vela-Ojeda J, Garcia-Ruiz Esparza MA, Reyes-Maldonado E, Jimenez-Zamudio L, Garcia-Latorre E, Moreno-Lafont M et al. Clinical relevance of NK, NKT, and dendritic cell dose in patients receiving G-CSF-mobilized peripheral blood allogeneic stem cell transplantation. Ann Hematol 2006; 85: 113-120.
31. Fehniger TA, Cooper MA, Nuovo GJ, Cella M, Facchetti F, Colonna M et al. CD56bright natural killer cells are present in human lymph nodes and are activated by T cell-derived IL-2: a potential new link between adaptive and innate immunity. Blood 2003; 101: 3052-3057.
32. Luo XH, Chang YJ, Xu LP, Liu DH, Liu KY, Huang XJ. The impact of graft composition on clinical outcomes in unmanipulated HLA-mismatched/haploidentical hematopoietic SCT. Bone Marrow Transplant 2009; 43: 29-36.
33. Muller S, Schulz A, Reiss U, Schwarz K, Schreiner T, Wiesneth M et al. Definition of a critical T cell threshold for prevention of GVHD after HLA non-identical PBPC transplantation in children. Bone Marrow Transplant 1999; 24: 575-581.
34. Kernan NA, Collins NH, Juliano L, Cartagena T, Dupont B, O'Reilly RJ. Clonable T lymphocytes in T cell-depleted bone marrow transplants correlate with development of graft-v-host disease. Blood 1986; 68: 770-773.
35. Huang XJ, Chang YJ, Zhao XY. Maintaining hyporesponsiveness and polarization potential of T cells after in vitro mixture of G-CSF mobilized peripheral blood grafts and G-CSF primed bone marrow grafts in different proportions. Transpl Immunol 2007; 17: 193-197.
36. Leung W, Iyengar R, Triplett B, Turner V, Behm FG, Holladay MS et al. Comparison of killer Ig-like receptor genotyping and phenotyping for selection of allogeneic blood stem cell donors. J Immunol 2005; 174: 6540-6545.
37. Verheyden S, Schots R, Duquet W, Demanet C. A defined donor activating natural killer cell receptor genotype protects against leukemic relapse after related HLA-identical hematopoietic stem cell transplantation. Leukemia 2005; 19: 1446-1451.